10-K: Elicio Therapeutics Amends Director Compensation Policy, Details Equity and Cash Awards

Elicio Therapeutics has amended its non-employee director compensation policy, outlining cash retainers, committee chair and member fees, and equity awards for board service.

Summary

• Elicio Therapeutics has updated its Non-Employee Director Compensation Policy, effective December 28, 2023.
• Non-employee directors are eligible for an annual retainer of $40,000.
• Additional annual retainers are provided for the Non-Executive Chairman ($35,000), Audit Committee Chair ($15,000), Audit Committee members ($7,500), Compensation Committee Chair ($10,000), Compensation Committee members ($5,000), Nominating and Corporate Governance Committee Chair ($8,000), and Nominating and Corporate Governance Committee members ($5,000).
• Retainers are earned quarterly and paid in arrears, not later than the 15th day following the end of each calendar quarter.
• Initial equity awards of options to purchase 8,200 shares are granted to new non-employee directors.
• Subsequent annual equity awards of options to purchase 4,100 shares are granted to continuing non-employee directors.
• Options vest over 36 months for initial awards and one year for subsequent awards, subject to continued service.
• Accelerated vesting occurs upon death, disability, or a change in control.
• The term of each stock option is ten years from the grant date.
• Non-employee directors are reimbursed for reasonable, documented out-of-pocket travel and business expenses.

Sentiment

Score: 7

Explanation: The document is neutral in tone, outlining a standard compensation policy. It is positive in that it provides clarity and structure for director compensation, but does not contain any information that would significantly impact the company's valuation.

Positives

• The policy provides clear guidelines for director compensation.
• Equity awards are designed to align director interests with those of shareholders.
• The policy includes provisions for accelerated vesting in certain circumstances.
• Reimbursement for expenses ensures directors are not out-of-pocket for their service.

Negatives

• The policy does not specify the exact value of the equity awards, which depends on the stock price at the time of grant.
• The policy does not address the potential for conflicts of interest arising from directors holding equity in the company.

Risks

• The policy may not be competitive enough to attract and retain high-quality directors.
• The value of equity awards may fluctuate, impacting the overall compensation of directors.
• Changes in the company's financial performance could affect the value of the equity awards.

Future Outlook

The policy will remain in effect until revised or rescinded by the Board, and may be amended, modified, or terminated at any time without advance notice.

Management Comments

• The compensation described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board.
• The terms and conditions of this Policy shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board.

Industry Context

This type of compensation policy is standard practice for publicly traded companies to attract and retain qualified board members. The specific amounts and terms are typical for a company of Elicio's size and stage.

Comparison to Industry Standards

• The annual retainer of $40,000 is within the typical range for biotech companies of similar size and stage.
• The additional retainers for committee chairs and members are also consistent with industry norms.
• The equity awards, while not specified in dollar value, are a common practice to align director interests with those of shareholders.
• Compared to companies like BioNTech or Moderna, Elicio's compensation structure is less complex, reflecting its earlier stage of development.
• The vesting schedules for options are standard, with accelerated vesting upon change of control being a common provision.

Stakeholder Impact

• Shareholders will benefit from having a clear and structured compensation policy for directors.
• Directors will be compensated for their service to the company.
• The policy ensures that directors are aligned with the interests of the company and its shareholders.

Next Steps

• The Board will continue to review and may amend the policy as needed.
• The company will implement the policy and grant awards to eligible directors.

Key Dates

Keywords

director compensation, equity awards, cash retainers, board of directors, stock options, committee fees, corporate governance, executive compensation